Search

everythinglearnresearchcommunity

for

Search:↓

Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.

Baricitinib may effectively treat oral lichen planus.

Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.

Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.

Baricitinib is a promising treatment for alopecia areata.

A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.

CTP-543 is generally safe for treating alopecia areata.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.

Baricitinib helps with severe hair loss, negative-pressure therapy lowers hernia recurrence, tranexamic acid reduces bleeding, robot-assisted breast surgery may improve outcomes, and acellular dermal matrix could decrease breast reconstruction complications.

IL-15 helps maintain hair growth and protects the immune status of hair follicles.

Most patients improved in both atopic dermatitis and alopecia areata with certain treatments, but some had worsened symptoms, suggesting personalized care is needed.

Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.

Alopecia areata is hard to treat, but new targeted therapies show promise.

Alopecia Areata is an unpredictable autoimmune hair loss condition with limited and variable treatment effectiveness.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Apremilast did not work for treating severe alopecia areata.

Low-dose tofacitinib is effective and cheaper for severe alopecia areata.

Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.

A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.

A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.

Baricitinib effectively treats certain skin conditions but may have serious side effects.

Alopecia areata involves complex immune and genetic factors, with potential treatment targets identified, but more research is needed.

Tofacitinib helped regrow hair in a lupus patient with alopecia.